Supplementary methods
The Optimum Patient Care Research Database (OPCRD) is a database containing anonymized, longitudinal medical record data in the UK, where patients' electronic medical records, incorporating primary, secondary, and hospitalization care data, are centralized at their primary care practices. S1 Used frequently in clinical research, the OPCRD contained anonymized data for 2.5 million patients at the time of this study, including about 750,000 patients with asthma from 525 primary care practices across England, Scotland, Wales, and Northern Ireland.
The study was conducted in compliance with all applicable local and international regulations and to standards suggested for observational studies, including an independent advisory group, use of an a priori analysis plan, study registration with commitment to publish, and a well-maintained and monitored study database. S2 The OPCRD is approved by the Health Research Authority of the UK NHS for clinical research use (REC reference: 15/EM/0150). The protocol for this study was approved by the Anonymised Data Ethics Protocols and Transparency (ADEPT) committee, the independent scientific advisory committee for the OPCRD (ADEPT approval code, ADEPT0415), and the study protocol was registered Figure S5) , children who experienced treatment failure before their first wheezing/asthma attack were censored at 7 days after the date of treatment failure. In addition, the inverse of treatment failure (ie, no additional therapy during the outcome year) was included as part of the "treatment stability" endpoint, defined in supplementary Table S1 .
The occurrence of pneumonia, recorded as a diagnostic Read code was an exploratory endpoint.
In addition, for the two controller comparisons (LTRA vs. ICS and EF ICS vs. fine-particle ICS), we calculated the asthma medication ratio, defined as the total number of controller units (ICS inhalers and 30-day LTRA prescriptions) divided by total controller plus reliever units (SABA inhalers). A ratio of ≥0.5 is considered appropriate prescribing for asthma management.
S9,S10 all courses where dosing instructions suggested wheezing/asthma attack (exacerbation) treatment (e.g. 6,5,4,3,2,1 reducing, or 30 mg as directed); and/or (c) all courses with no dosing instructions, but unlikely to be maintenance therapy because of prescription strength or frequency of prescriptions. Maintenance therapy was defined as prescriptions with daily dosing instructions of ≤10mg prednisolone or prescriptions for 1 mg or 2.5 mg prednisolone tablets where daily dosing instructions were not available.
Abbreviations: ED, emergency department; ICS, inhaled corticosteroid; LABA, long-acting β 2 -agonist; LTRA, leukotriene receptor antagonist; SABA, short-acting β 2 -agonist.
Cohort matching
Cohort matching was conducted by exact matching on key demographic, clinical, and baseline year variables. The selection of matching variables was informed by expert clinical advice and previous research experience, as previously reported. S6-S8,S11 Different matching ratios were evaluated, and the ratios were chosen to maximize the numbers of patients in each cohort, with the goal of optimizing statistical power. Supplementary Figures S1-S4 depict the sequence in which matching criteria were applied, one variable at a time: namely, age on the index date (in years), sex, year of the index date, mean daily number of SABA doses (2 puffs, or 200 µg) during the baseline year, wheezing/asthma attacks during the baseline year (yes/no), acute antibiotic prescriptions during the baseline year (yes/no), and ever-recorded eczema (yes/no). The final step was the random selection of matched pairs, excluding duplicate matches, through the use of custom software ( Figures S1-S4 ). Figure S4 . Patient flow chart: extrafine-particle inhaled corticosteroid (ICS) vs. fine-particle ICS comparison. The numbers for the extrafine-particle and fine-particle ICS cohorts represent the actual number of children. The final step was the random selection of matched pairs, excluding duplicate matches, through the use of custom software. 
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Notes:
a Matched cohorts were compared using conditional logistic regression. b The number of SABA doses in issued prescriptions were averaged during the outcome year. One SABA dose was defined as 200 µg (two puffs).
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c The median daily ICS dose exposure during the outcome year was calculated using the total ICS dose in prescriptions over 365 days. The doses of ICS were standardized to equivalence with fluticasone; thus, the actual doses of fluticasone, ciclesonide, and extrafine-particle beclomethasone were used, and doses of budesonide and non-extrafine beclomethasone were halved. d The count of spacer prescriptions included those on the index date or during the outcome year (not during baseline year).
Abbreviations: ICS, inhaled corticosteroid; IQR, interquartile range; LTRA, leukotriene receptor antagonist; n/a, not assessed; SABA, shortacting β-agonist. 
Notes:
a Matched cohorts were compared using conditional logistic regression. b Treatment stability data were missing for 42 (15.3%) and 210 (19.1%) children in EF ICS and fine-particle ICS cohorts, respectively, and for 14 (13.5%) in the ICS cohort. Controller:total asthma medication ratio data were missing for 65 (5.9%) children in the fine-particle ICS cohort and for 5 (4.8%) and 11 (10.6%) children in LTRA and ICS cohorts, respectively. c The number of SABA doses in issued prescriptions were averaged during the outcome year. One SABA dose was defined as 200 µg (two puffs). d The median daily ICS dose exposure during the outcome year was calculated using the total ICS dose in prescriptions over 365 days. The doses of ICS were standardized to equivalence with fluticasone; thus, the actual doses of fluticasone, ciclesonide, and extrafine-particle beclomethasone were used, and doses of budesonide and non-extrafine beclomethasone were halved. e The count of spacer prescriptions included those on the index date or during the outcome year (not during baseline year).
Abbreviations: EF, extrafine; ICS, inhaled corticosteroid; IQR, interquartile range; LTRA, leukotriene receptor antagonist; n/a, not assessed; SABA, short-acting β-agonist. Figure S5 . Time to first wheezing/asthma attack (exacerbation): inhaled corticosteroid (ICS) vs. shortacting β-agonist (SABA). Children who experienced treatment failure (addition of new therapy or ≥50% increase in dose of index date therapy) before an attack were censored at 7 days after the date of treatment failure. Figure S6 . Time to first wheezing/asthma attack (exacerbation): leukotriene receptor antagonist (LTRA) vs. short-acting β-agonist (SABA). Children who experienced treatment failure (addition of new therapy or ≥50% increase in dose of index date therapy) before an attack were censored at 7 days after the date of treatment failure. Figure S7 . Time to first wheezing/asthma attack (exacerbation): leukotriene receptor antagonist (LTRA) vs. inhaled corticosteroid (ICS). Children who experienced treatment failure (addition of new therapy or ≥50% increase in dose of index date therapy) before an attack were censored at 7 days after the date of treatment failure. Figure S8 . Time to first wheezing/asthma attack (exacerbation): extrafine-particle inhaled corticosteroid (EF ICS) vs. fine-particle (FP) ICS. Children who experienced treatment failure (addition of new therapy or ≥50% increase in dose of index date therapy) before an attack were censored at 7 days after the date of treatment failure.
